Re: Zenith ZEN-3694/Enzalutamid... mCRPC Phase 1b/2a Study Published

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith ZEN-3694/Enzalutamid... mCRPC Phase 1b/2a Study Published

posted on Jul 28, 2020 10:09PM

Nice find Jonzobot. According to slide 26 of today's presentation, the newly listed trial (https://clinicaltrials.gov/ct2/show/NCT04471974) will be in addition to the planned "Randomized study of ZEN-3694 + enzalutamide in prostate cancer patients (early 2021)."

https://www.zenithepigenetics.com/upload/media_element/122/01/zenith-epigenetic-therapeutic-targets-2020-final.pdf

7 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply